Features of patients undergoing HDM/SCT and TRM during the first 10 years compared with the last 5 years
| Feature . | All (N = 421) . | 1994-2003 (N = 297) . | 2004-2008 (N = 124) . | P . |
|---|---|---|---|---|
| Age ≥ 65 y, % | 17.3 | 17.2 | 17.7 | .88 |
| Creatinine > 2 mg/dL, % | 17.1 N = 374 | 14.6 N = 260 | 22.8 N = 114 | .05† |
| Time from diagnosis to SCT, months, median (range) | 5.2 (1-143) | 5.3 (1-143.5) | 4.5 (1.6-107) | .03† |
| Cardiac involvement, % | 45 | 41.4 | 54 | .01† |
| Dominant cardiac involvement, % | 16.8 | 17.2 | 16.1 | .89 |
| ≥ 3 organs involved, % | 43 | 43.7 | 41 | .61 |
| Full-dose melphalan, % | 55 | 55.9 | 52.4 | .51 |
| BNP > 100 pg/mL,* % | 54.3 | — | 54.3 | — |
| TRM, % | 11.4 | 13.8 | 5.6 | .01 |
| Feature . | All (N = 421) . | 1994-2003 (N = 297) . | 2004-2008 (N = 124) . | P . |
|---|---|---|---|---|
| Age ≥ 65 y, % | 17.3 | 17.2 | 17.7 | .88 |
| Creatinine > 2 mg/dL, % | 17.1 N = 374 | 14.6 N = 260 | 22.8 N = 114 | .05† |
| Time from diagnosis to SCT, months, median (range) | 5.2 (1-143) | 5.3 (1-143.5) | 4.5 (1.6-107) | .03† |
| Cardiac involvement, % | 45 | 41.4 | 54 | .01† |
| Dominant cardiac involvement, % | 16.8 | 17.2 | 16.1 | .89 |
| ≥ 3 organs involved, % | 43 | 43.7 | 41 | .61 |
| Full-dose melphalan, % | 55 | 55.9 | 52.4 | .51 |
| BNP > 100 pg/mL,* % | 54.3 | — | 54.3 | — |
| TRM, % | 11.4 | 13.8 | 5.6 | .01 |